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Abstract
Background: c-Met and EGFR receptors are widely expressed on cancer cells; they are implicated in the 
development and progression of cancer through a plethora of effects on cell cycle progression, apoptosis, 
motility and metastasis and are potential targets for combination therapy. EGFR receptor tyrosine 
kinases are currently being targeted in a number of malignancies. Methods: Apoptosis was studied by 
FACS analysis using propidium iodide. EGF and HGF signaling intermediates were studied by western 
blotting. Cell proliferation was determined by MTT assays. Cell motility was done by time lapse confocal 
microscopy. Results: c-Met and EGFR were both expressed in A549, H1838, H2170, SW900, SW1573, 
H358, SKLU-1, and H1993 non small cell lung cancer (NSCLC) cell lines. Both EGF and HGF at 100 ng/ml 
in medium showed a synergistic effect on cell proliferation at 48–72 h as seen by a proliferation assay in 
A549, H1838, and SKMES cells. In A549 and H1838 cell lines, HGF (40 ng/ml) and EGF (5 ng/ml) induced 
synergistic phosphorylation on c-Met (Tyr 1003/1230/1234/1235). Additionally, synergistic phosphorylation 
of Akt (Ser-473) and phospho-ERK1+ERK2 (Thr202/Tyr204) was also seen indicating that EGF and HGF 
could induce synergistic phosphorylation of important signaling intermediates. Treatment with EGF and 
HGF at 100 ng/ml for 2 h also leads to an additive effect in inducing cell motility (especially membrane 
rufﬂ  ing) in H1993 cells. A novel c-Met small molecule tyrosine kinase inhibitor SU11274 and EGFR tyrosine 
kinase inhibitors Tyrphostin AG1478 and geﬁ  tinib (Iressa) were tested to study their effect in combination 
on proliferation and apoptosis in lung cancer cells. Interestingly, a synergistic effect on inhibition of cell 
proliferation was seen in the presence of SU11274 and Tyrphostin AG1478. 0.5 µM Tyrphostin AG1478 
and 2 µM SU11274 inhibited growth by 21% and 25%, respectively; a combination of both tyrosine kinase 
inhibitors inhibited growth by 65%. Interestingly, EGFR inhibitor (geﬁ  tinib, Iressa) and c-Met inhibitor 
(SU11274) also had a synergistic effect on apoptosis in H358 cells. Conclusion: There was a synergistic 
effect of EGF and HGF on proliferation, downstream activation of signal transduction and an additive effect 
seen on motility. These studies show that a combination of HGF and EGF tyrosine kinase inhibitors on 
NSCLC, could potentially be targeted in a synergistic fashion. 
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Introduction
NSCLC is a devastating malignancy for which current therapies 
do not offer satisfactory results. It is imperative to develop 
novel therapeutic targets in order to achieve better outcomes 
for this disease. The molecular targeting of RTKs has emerged 
as a promising approach to the treatment of NSCLC. c-Met 
and EGFR are known to be expressed and also play a very 
important role in the progression of NSCLC.[1,2] EGFR, in 
particular, has been extensively investigated, and its inhibitors 2 2
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have undergone clinical trials with limited success.[3] We have 
previously shown that the c-Met pathway plays a crucial role 
in the progression of SCLC,[4,5] NSCLC, and other invasive 
tumors.[6] 
The EGFR protein is a 170-kD transmembrane glycoprotein, 
consisting of an extracellular ligand binding domain, a 
transmembrane domain, and an intracellular tyrosine kinase 
domain.[7] The receptor is part of a family of human epidermal 
growth factor receptors, which has four members (HER1/
erbB1, HER2/erbB2, HER3/erbB3, and HER4/erbB4). EGFR 
has six members , currently known endogenous ligands: EGF, 
amphiregulin, TGF-α, betacellulin, heparin binding EGF, 
and epiregulin.[8] When the ligand binds the receptor, the 
receptor undergoes homodimerization, or heterodimerization 
(commonly with HER2), and causes autophosphorylation of 
the tyrosine kinase domain and activation of critical signal 
transduction events, ultimately leading to a biological response. 
The EGFR inhibitor, gefitinib has been used as a single agent 
in NSCLC, but overall, the efficacy has been modest at best. 
However, there are a select group of patients that respond very 
dramatically to this agent, and very recently, these responses 
were correlated to the presence of activating mutations in the 
tyrosine kinase domain of EGFR in these tumors.[9,10] 
c-Met is also highly overexpressed in 60%–80% of NSCLC 
and overexpressed in many solid tumors.[11] The c-Met receptor 
is a disulfide linked α-β heterodimer with a molecular weight 
of 190 kD.[12] The 140-kD β chain spans the membrane and 
possesses cytoplasmic tyrosine kinase activity and can be 
detected in its precursor form at 170 kD. Unlike EGFR, the 
only known natural ligand for c-Met is HGF (also known as 
scatter factor).[13–15] HGF stimulation of c-Met can lead to 
proliferation, increased survival, altered motility, enhanced 
invasion into extracellular matrix, and more rapid formation 
of tubules.[15] c-Met overexpression as well as activating 
mutations in the various domains can lead to carcinogenesis 
in multiple tumors. There are multiple activating mutations 
in the c-Met gene identified in hereditary papillary renal 
carcinomas.[16] On activation by autophosphorylation, c-Met 
can associate with and activate multiple signal transduction 
intermediates.[15] Novel small molecule inhibitors of c-Met, 
SU11274,[17] and PHA-665752[18] have been utilized in an in 
vitro setting and have shown to inhibit the phosphorylation of 
c-Met and also inhibit the proliferation of cell lines. 
c-Met co-immunoprecipitates with EGFR in protein extracts 
from tumor cells but not in extracts from normal hepatocytes, 
suggesting a new tumor-specific cross-talk for the activation 
of HGF/MET signaling by the TGFα/EGFR axis.[19] Recently, 
several papers suggest an interaction between HGF/MET and 
EGFR signaling pathways. In a glioma cell line, c-Met activation 
results in a wave of transcription-dependent EGFR activation, 
which contributes to HGF-induced cell proliferation.[20] In 
mammary carcinoma cells, EGFR inhibition significantly 
blocked HGF activation of c-Met and EGFR and inhibition 
of these pathways mitigated HGF-induced proliferation and 
motility.[21] HGF can induce transactivation of EGFR in corneal 
epithelial cells through amphiregulin and heparin-binding 
epidermal growth factor-like growth factor, and this is a 
prerequisite for induction of full motility.[22] It has also been 
found that cross-talk between EGFR and c-Met may play a key 
role in regulating retinal pigment epithelium cell migration, 
proliferation, and wound healing.[23] In addition, a recent study 
showed that c-Met amplification leads to gefitinib secondary 
resistance and could be an explanation for this resistance in 
some patients. It was found in NSCLC that amplification of 
c-Met causes gefitinib resistance by driving ERBB3 (HER3)-
dependent activation of PI3K, a pathway thought to be specific 
to EGFR/ERBB family receptors.[24] Recently, second-site 
point mutations (T790M) associated with 50% of the cases 
with acquired resistance to EGFR tyrosine kinase inhibitors 
have been found in lung adenocarcinomas harboring EGFR 
mutations in exons encoding the tyrosine kinase domain. It has 
also been found that c-Met amplification occurs independent 
of EGFRT790M mutations and that c-Met may be a clinically 
relevant therapeutic target for some patients with acquired 
resistance to gefitinib or erlotinib.[25] Rikova et al. have 
suggested using a global survey of phosphotyrosine signaling 
based on activated kinases identified that in a given tumor, 
there are opportunities to therapeutically intervene using 
multiple kinase inhibitors.[26]
Our rationale behind the investigation of the interaction 
between c-Met and EGFR are multifold. Both receptors are 
overexpressed in NSCLC and both have been implicated 
in cell motility, generation of reactive oxygen species,[5,27] 
angiogenesis[4,28] and several other critical biological 
phenomena. Since there are many common signaling pathways 
between both receptors, we sought to determine if EGF and 
HGF could synergistically/cooperatively lead to increased 
cellular proliferation, motility, as well as downstream 
signaling. EGFR inhibitors have been used and continue to 
be used clinically, and have shown only a modest benefit in 
the treatment of NSCLC.[3] With the advent of a novel small 
molecule inhibitor of c-Met, SU11274, we thought that in 
respect to the interactions between EGFR and c-Met, it 
would be crucial to demonstrate a synergistic inhibition of cell 
growth and apoptosis utilizing the respective inhibitors. Our 
demonstration of the functional and biochemical interaction 
between c-Met and EGFR and the synergism between their 
inhibitors will rationalize the future combination of these 
drugs in the management of NSCLC.3 3
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Materials and Methods
Reagents and antibodies: SU11274: [(3Z)-N-(3-
chlorophenyl)-3-({3,5-dimethyl-4-[(4-methylpiperazin-1-yl)
carbonyl]-1H-pyrrol-2-yl}methylene)-N-methyl-2-oxo-2,3-
dihydro-1H-indole-5-sulfonamide] and gefitinib were obtained 
from American Customs Chemical Corporation (San Diego, 
CA). Tyrphostin AG1478 was obtained from Sigma-Aldrich 
(St. Louis, MO). All inhibitors were suspended in DMSO 
and kept in small aliquots at –20°C. HGF was obtained from 
EMD chemical (Gibbstown, NJ), and EGF was obtained 
from Invitrogen (Carlsbad, CA). Phosphospecific antibodies 
for pS473 on AKT were obtained from Cell Signaling 
Technology (Beverly, MA). Total c-Met was obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA) and ß-actin 
from Sigma-Aldrich (St. Louis, MO). Phospho c-Met 
(Tyr 1230/1234/1235), phospho c-Met (Tyr 1003), and 
phospho-ERK1+ERK2 (Thr202/Tyr204) were obtained 
from Invitrogen (Carlsbad, CA). All antibodies were used as 
described in the manufacturer’s protocol.
Cell lines and apoptosis analysis
All NSCLC cell lines A549, H1838, H2170, SW900, 
SW1573, H358, SKLU-1, and H1993 were obtained from 
the American Type Culture Collection (Rockville, MD, 
USA), and were cultured according to the instructions 
(http://www.ATCC.org).
Cell lines were incubated at 37°C and 5% CO2. For studying 
the effect of Iressa (gefitinib) and SU11274 alone and in 
combination, H358 cells were plated in 6 well plates and 
treated after 24 h with different concentrations of Iressa and 
SU11274. After 72 h of treatment, cells were collected by 
trypsinization, stained with propidium iodide and the sub-G0 
DNA content was determined by FACS analysis and analyzed 
by Cell-Quest software.
Kinetics of HGF- and EGF-induced 
phosphorylation of c-Met and downstream 
mediators
Cells were starved overnight in media containing 0.5% BSA 
(w/v) (Sigma, St. Louis, MO, USA) for 18 h. The cells were 
then stimulated with 40 ng/ml HGF or 5 ng/ml of EGF or both 
for various intervals of time and lysed in lysis buffer containing 
20 mmol/L Tris (pH, 8.0), 150 mmol/L NaCl, 10% glycerol, 
1% NP40, 0.42% NaF, 1 mmol/L phenylmethylsulfonyl 
fluoride, 1 mmol/L Na3VO4, and 10 µL/mL protease inhibitor 
cocktail (Sigma-Aldrich) as described previously.[5] Cell lysates 
were separated by 7.5% or 10% SDS-PAGE under reducing 
conditions. Proteins were transferred to an immobilization 
membrane (Bio-Rad Laboratories, Hercules, CA) and 
immunoblotted using the enhanced chemiluminescence 
technique (PerkinElmer Life and Analytical Sciences, 
Torrence, CA). The membrane was then probed with the 
antibodies against p-Akt (Serine 473), phospho c-Met (Tyr 
1230/1234/1235), phospho c-Met (Tyr 1003), phospho-
ERK1+ERK2 (Thr202/Tyr204), and ß-actin. 
MTT assays
To study the synergistic effects of HGF and EGF and the effect 
of inhibitors of EGFR and c-Met on cell growth, cell viability 
was measured by a MTT colorimetric dye reduction assay 
(Sigma, St. Louis, MO) using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) (MTT) according to 
the manufacturer’s instructions. Each experiment was done in 
four replicate wells for each drug concentration. The IC50 value 
is defined as the concentration needed for a 50% reduction 
in absorbance calculated from the growth curves. Each data 
point is representative of three independent experiments, and 
the standard deviations were calculated accordingly. To study 
the synergistic effect of HGF and EGF, cells (5000 cells/well) 
were plated in a 96-well plate. After 24 h, wells were treated 
with HGF 100 ng/ml, EGF 100 ng/ml or both in medium 
with 10% FBS. At given intervals of time, cell viability was 
measured by adding MTT reagent and solubilization solution, 
and the plates were read at 570 nm. Percentage of cell viability 
was determined relative to the control which had no additional 
growth factors. To determine the inhibitory effects of EGFR 
inhibitor Tyrphostin AG1478 and c-Met inhibitor, H2170 cells 
were plated as described above and treated after 24 h with 
various concentrations of Tyrphostin and SU11274 for 72 h 
after which an MTT was performed. All drug inhibition studies 
to study proliferation were performed in media containing 
10% FBS.
Motility studies using time lapse video microscopy
For the motility studies, H2170 cells were plated in 35 mm 
glass bottom dishes (MatTek Co., Ashland, MA) coated with 
collagen. Cells were allowed 12 h to adhere to the plate and 
were subsequently starved in serum-free medium containing 
0.5% BSA for 24 h. Cells were pre-incubated for 2 h prior to 
imaging with HGF alone (100 ng/ml), EGF alone (100 ng/ml), 
and HGF + EGF at the same doses. Images were taken by using 
a Zeiss time lapse video microscope. Data was analyzed and 
quantified using Metamorph and Image J (NIH). 
Results
EGFR and c-Met expression in NSCLC cell lines
The expression of EGFR and c-Met were determined by 
immunoblotting of whole cell lysates prepared from cells 
cultured in regular media. EGFR and c-Met were both expressed 
at variable levels in the entire group of 8 cell lines tested 
[Figure 1]. EGFR expression was the highest in H2170, 4 4
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and c-Met expression was the highest in H1993 [Figure 1]. 
H2170, A549, and H1838 had robust expression of both 
c-Met and EGFR and were used for several investigations on 
signal transduction, cell viability, cell proliferation, and cell 
motility.
EGF and HGF effect on the growth of NSCLC cell 
lines
The effect of HGF and EGF on cell growth was studied by 
treating cells with 100 ng of EGF or HGF either alone or in 
combination, and cell proliferation was determined by MTT 
as described in the section Materials and Methods [Figure 
2A–C]. In A549, H1838, and SKMES cells, a combination 
of HGF and EGF had a synergistic effect (90%, 230% and 
80%, respectively) [Figure 2A–C]. A synergistic effect can 
be defined as an effect that is more than the additive effect of 
HGF and EGF alone. These results indicate that there was a 
synergistic proliferative effect of both cytokines combined. 
These results could be due to potential cross-talks of HGF 
and EGF signaling pathways with each other and with other 
protumorigenic factors that have been shown to promote tumor 
cell growth. Functions of distinct signaling pathways such as 
proliferation can be amplified since cytoplasmic downstream 
components of most growth factor ligand/receptor complexes 
(e.g., adaptor proteins, kinases, and transcription factors) are 
frequently utilized by more than one signaling pathway.[29]
HGF and EGF induce synergistic phosphorylation 
of c-Met receptor and of downstream signaling 
intermediates in a synergistic fashion
In the NSCLC cell lines, H1838 and A549, we studied 
the phosphorylation of HGF receptors and several of their 
downstream signaling intermediates [Figure 3A–C]. After 
densiometric analysis using NIH image we determined 
that HGF and EGF induced synergistic phosphorylation of 
phospho-c-Met (Tyr 1003) [Figure 3A, B] and phospho-c-
Met (Tyr 1230/1234/1235) [Figure 3B]. This synergistic 
phosphorylation of HGF receptor could occur due to the 
association of c-Met with EGFR in tumor cells[19] or due 
to transcription-dependent cross-talk between c-Met and 
EGFR,[20] which could facilitate synergistic phosphorylation 
of these growth factor receptors. 
Figure 1: Expression of EGFR and c-Met in NSCLC cell lines. 
Whole cell lysates were prepared from 8 NSCLC cell lines, grown 
in media containing 10% FBS. Cell lines include A549, H1838, 
H2170, SW900, SW1573, H358, SKLU-1, and H1993. Expression of 
EGFR and c-Met was examined by immunoblotting as described 
in the Material and Methods section using polyclonal EGFR and 
c-Met antibodies. The c-Met immunoblot shows an upper 170-
kDa protein band which represents the precursor form of the 
glycosylated c-Met and the lower 145-kDa band which is the 
biologically active transmembrane ß-subunit of c-Met. ß-actin 
was used as an internal loading control
Figure 2: HGF and EGF stimulate growth in a synergistic manner in the NSCLC cell lines. A549 (A), H1838 (B), and SKMES (C) cells 
(5000 /well) were plated in 96-well plates. After 24 h, wells were treated with HGF 100 ng/ml, EGF 100 ng/ml or both in medium with 
10% FBS. At given intervals of time, viable cells were detected by MTT assays and cell viability was plotted as a mean ± SD of three 
independent experiments. Percentage of cell viability was determined relative to the control that had no additional growth factors. 
HGF and EGF both induced cell proliferation, and a combination of HGF and EGF had a synergistic effect on cell proliferation in A549 
(A), H1838 (B), and SKMES (C)5 5
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Synergistic phosphorylation of Akt (Serine 473) and phospho-
ERK1+ERK2 (Thr202/Tyr204) [Figure 3A, C], which are 
downstream signaling intermediates from growth factor 
receptors, were also seen by densitometric analysis.
HGF and EGF cooperatively induce increased 
membrane rufﬂ  ing
In order to study the changes in the cytoskeleton that occur via 
the c-Met/HGF axis and the EGFR/EGF axis, we studied cell 
motility by time lapse video microscopy. The images shown 
in the lower panel of Figure 4 are displayed in false color.  An 
increase in membrane ruffling is observed with an increase in 
red color and a decrease is indicated by presence of blue color, 
as seen in the bar on the side of Figure 4. There was evidence 
of increased membrane ruffling that occurred when cells were 
stimulated with HGF and EGF independently and an additive 
effect when used together [Figure 4].
c-Met kinase inhibitor SU11274 and EGFR kinase 
inhibitors Tyrphostin AG1478 or geﬁ  tinib synergize 
to inhibit proliferation of NCI-H2170 NSCLC cell 
lines 
Due to the common signaling pathways that are regulated by 
HGF and EGF, we were interested in studying if the inhibitors 
of these RTKs, Tyrphostin AG1478, and SU11274 could 
potentially be synergistic in their ability to inhibit proliferation 
of NSCLC cells. The IC50 for each drug was first determined 
by MTT assays (data not shown) and was determined to be 4 
µM for SU11274 and 1 µM for Tyrphostin AG1478. Both drugs 
were used independently and simultaneously in the same dosing. 
Interestingly, a synergistic effect on inhibition of cell proliferation 
was seen in the presence of SU11274 and Tyrphostin. 0.5 µM 
Tyrphostin and 2 µM SU11274 inhibited growth by 21.5% and 
25.5%, respectively; a combination of both tyrosine kinase 
inhibitors inhibited growth by 65.2%. There was no indication 
of antagonism with any of the doses utilized. 
SU11274 and geﬁ  tinib induce apoptosis in NSCLC 
cell line H358 in a synergistic fashion
Growth factor signal pathways are one of the main regulators 
of cell proliferation and apoptosis, and hence, we studied the 
effect of a combination of an EGFR inhibitor (gefitinib) and 
c-Met inhibitor (SU11274) on apoptosis in H358 cells. The 
cells were treated as described earlier with Iressa and SU11274 
alone and in combination after which cells were stained with 
propidium iodide and the sub G0 DNA content was determined 
by FACS analysis. As shown in Figure 5A and 5B, Iressa and 
SU11274 have a synergistic effect on apoptosis. 
Discussion
Receptor tyrosine kinase (RTK) inhibition is becoming 
Figure 3. Kinetics of HGF- and EGF-induced phosphorylation, c-Met receptor, and its downstream signaling proteins. A549 and H1838 
cells were starved overnight in media containing 0.5% BSA for 18 h and were stimulated with 40 ng/ml HGF or 5 ng/ml of EGF or both 
for various intervals of time. Cell lysates were prepared and western blotting performed as described in materials and methods section 
(A). In A549 cells, synergistic phosphorylation of c-Met (Tyr 1003) and downstream signaling protein Akt (Serine 473) was observed 
at 2.5 min after stimulation with a combination of EGF and HGF (B). In H1838 cells, HGF and EGF together induced synergistic 
phosphorylation of phospho c-Met (Tyr 1003) and phospho c-Met (Tyr 1230/1234/1235). (C) Synergistic phosphorylation of Akt (Serine 
473) and ERK1+ERK2 (Thr202/Tyr204), which are downstream signaling intermediates
Figure 4: Increased membrane rufﬂ  ing observed with HGF and 
EGF.  H1993 were plated in glass bottom dishes coated with 
collagen (150,000 cells/plate). They were grown in serum-free 
medium containing 0.5% BSA for 24 h after which each plate was 
pretreated for 2 h with 100 ng/ml EGF, HGF or both. Cells were 
studied under TLVM for 4 h and photographs were taken at 1-min 
intervals. Cell movement with changing shape was analyzed using 
NIH image analysis. Images in the lower panel were created with 
false colors according to the movement and change in shape of 
cells.  An increase in membrane rufﬂ  ing was seen by an increase in 
red color, and a decrease is indicated by presence of blue color as 
observed in the bar on the side of Figure 4. Increased membrane 
rufﬂ  ing was seen when cells were incubated with HGF or EGF and 
an additive effect was observed by a combination of both6 6
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very important in therapy for cancer. We identify here that 
both EGFR and c-Met RTKs were expressed in lung cancer, 
and they can cooperate to enhance cell biological functions 
such as proliferation, cell motility, and downstream signal 
transduction (such as the Akt/S6 kinase, ERK1/2, and 
focal adhesion protein pathways). Importantly, inhibition of 
both the receptors leads to enhanced growth inhibition and 
apoptosis.
c-Met RTK has been shown to play an important role in 
the pathogenesis and progression of a number of solid 
tumors.[30] It also has potent angiogenic properties.[31] Previously, 
we have shown that c-Met can be overexpressed, activated (as 
measured by phosphorylation of the catalytic domain as well 
as juxtamembrane domain), mutated (in the semaphorin 
or juxtamembrane domains), and/or amplified in lung 
cancers.[32,33] Also, inhibition of c-Met with siRNA or small 
molecule inhibitors leads to decreased cell growth and 
apoptosis of lung cancer cells.[33] We have previously shown that 
there also can be synergism of c-Met inhibition with mTOR 
inhibition (with rapamycin) in activated c-Met cells, including 
lung cancer.[34] Importantly, we show here that inhibition of 
c-Met is synergistic with EGFR inhibition. This was reflected 
by the effects on cell growth as well as apoptosis. EGFR plays a 
crucial role in the progression of lung cancer, and therapeutic 
inhibition has come to clinical fruition with agents such as 
erlotinib, gefitinib, and cetuximab.[35,36] 
EGFR can be targeted in a number of tumors, especially in 
lung cancer.[35,36] There have been somatic mutations of EGFR 
in the tyrosine kinase domain reported and amplification of 
the gene; these have been linked to therapeutic response to 
small molecule inhibitors.[9,10] An emerging theme has also 
been resistance to EGFR inhibition and the necessity of other 
combinational strategies. With the data presented here, 
the combination of EGFR and c-Met inhibition would be a 
useful strategy to pursue in clinical trials. Also, it would be 
interesting to determine how this would relate to combination 
with cytotoxic chemotherapies such as cisplatin, taxanes, and 
pemetrexed (all effective therapies in lung cancer). 
Since EGFR can be mutated in the tyrosine kinase domain[9,10] 
and c-Met in the non-tyrosine kinase domains in NSCLC,[33] it 
would be important to study the biological/biochemical effects 
and therapeutic inhibition of these mutations in combination. 
It would also be important to study if mutations of c-Met 
and EGFR in NSCLC are concordant or mutually exclusive 
in NSCLC. For example, in a majority of NSCLC, K-ras 
mutations and EGFR appear to be mutually exclusive.[37] We 
have certainly studied the EGFR/c-Met pathways in NSCLC, 
and it would be important to study the biological and signal 
transduction pathways in normal human bronchial epithelial 
Figure 5: SU11274 and Tyrphostin AG1478 inhibit growth in a synergistic manner in H2170. SU11274 and geﬁ  tinib induce apoptosis 
in a synergistic manner in H358 cells. (A) Intially, studies were performed on a combination of drugs and the IC50 for SU11274 and 
Tyrphostin AG1478 for the cell line H2170 was determined; further, the drugs were diluted in medium with 10% FBS. H2170 cells 
(5000 cells/well) were plated in a 96-well plate, and after 24 h, wells were treated with varying concentrations of tyrphostin, SU11274 
or both in medium with 10% FBS. At 72 h, cell viability was performed by an MTT assay. Percentage of viable cells were determined 
relative to the control which had no additional growth factors. As shown in (A), synergistic effect on inhibition of cell proliferation 
was observed with 0.5 µM Tyrphostin and 2 µM SU11274. (B) H358 cells were plated in 6-well plates and treated after 24 h with 
various concentrations of Iressa and SU11274 as indicated. After 72 h of treatment, cells were collected by trypsinization, stained with 
propidium iodide, and the sub-G0 DNA content was determined by FACS analysis and analyzed by Cell-Quest software. As shown in 
Figure 5B, geﬁ  tinib and SU11274 have a synergistic effect on apoptosis7 7
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cells with and without smoking to determine if smoking also 
plays an important role in the cross-talk between these two 
receptors.
Lung cancers have remarkable ability for metastasis. For 
example, over 1/3 of patients with NSCLC present with 
metastatic disease beyond the chest cavity.[38] RTKs play 
an important role in metastases-especially c-Met[39] and 
EGFR.[40] Cell motility and migration of lung cancer cells 
are the first initial mechanisms of metastasis. We show here 
that cell motility and membrane ruffling of NSCLC cells was 
enhanced in combination with c-Met and EGFR activation. 
It would now also be important to determine the signal 
transduction pathways involving the focal adhesion proteins 
in the context of EGFR/c-Met signaling and determine the 
effects in vivo as related to metastasis. Ultimately, one could 
envision that inhibition of both of these RTKs could lead to 
decreased metastasis in lung cancers.
Conclusion
c-Met and EGFR receptors are widely expressed in several 
NSCLC cell lines. In NSCLC, HGF and EGF exhibited 
synergistic effects on proliferation, phosphorylation of c-Met 
and also important signaling intermediates. Interestingly, 
c-Met and EGFR inhibitors synergistically inhibited cell 
proliferation and promoted apoptosis in NSCLC. Additive 
effects of HGF and EGF on cell motility were also observed. 
These studies demonstrate that HGF and EGF tyrosine kinase 
inhibitors could be synergistic targets in the treatment of 
NSCLC
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